Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Reduced Dose Post Transplantation Cyclophosphamide as GvHD Prophylaxis in Adult Patients With Hematologic Malignancies Receiving HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

NCT06001385 is registered in ClinicalTrials.gov with Center for International Blood and Marrow Transplant Research as lead sponsor.

NCT NCT06001385
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06001385 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Reduced Dose Post Transplantation Cyclophosphamide as GvHD Prophylaxis in Adult Patients With Hematologic Malignancies Receiving HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
Lead sponsor
Center for International Blood and Marrow Transplant Research
Phase
Phase 2
Overall status
Active, not recruiting
Start date
December 8, 2023
Completion date
December 30, 2026
Enrollment
313 (estimated)
Sites
32

Conditions

As the registry lists them; a condition with its own page is linked.

acute leukemia, acute lymphoblastic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, chronic myelomonocytic leukemia, lymphoma, myelodysplastic syndromes, myelofibrosis, myeloproliferative neoplasm, pro-lymphocytic leukemia